Evidence map›Paper›PMID 27120191›Full record

ReviewKnee surgery, sports traumatology, arthroscopy : official journal of the ESSKA2016

Regenerative approaches for the treatment of early OA.

L de Girolamo, E Kon, G Filardo, A G Marmotti, F Soler, G M Peretti, F Vannini, H Madry, S Chubinskaya

Abstract readReview
PubMed Publisher
In one paragraph

Review in Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Regenerative medicine for early osteoarthritis.Therapeutic advances in musculoskeletal disease · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

L de GirolamoOrthopaedic Biotechnology Laboratory, Galeazzi Orthopaedic Institute, Milan, Italy. laura.degirolamo@grupposandonato.it.
E KonII Orthopedic Division and NanoBiotechnology Lab, Rizzoli Orthopedic Institute, Bologna, Italy.
G FilardoII Orthopedic Division and NanoBiotechnology Lab, Rizzoli Orthopedic Institute, Bologna, Italy.
A G MarmottiDepartment of Orthopaedics and Traumatology, University of Torino, Turin, Italy.
F SolerITRT Centro Médico Teknon, Barcelona, Spain.
G M PerettiDepartment of Biomedical Sciences for Health, University of Milan, Milan, Italy.
F VanniniI Clinic of Orthopaedics and Traumatology, Rizzoli Orthopaedic Institute, Bologna, Italy.
H MadryCenter of Experimental Orthopaedics, Saarland University, Homburg/Saar, Germany.
S ChubinskayaDepartment of Pediatrics, Rush University Medical Center, Chicago, IL, USA.
Istituto Ortopedico Rizzoli · ITHospital Quirón Teknon · ESIstituto Ortopedico Galeazzi · ITRush University Medical Center · USSaarland University · DEUniversity of Milan · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diagnosis and the prompt treatment of early osteoarthritis (OA) represent vital steps for delaying the onset and progression of fully blown OA, which is the most common form of arthritis, involving more than 10 % of the world's population older than 60 years of age. Nonsurgical treatments such as physiotherapy, anti-inflammatory medications, and other disease-modifying drugs all have modest and short-lasting effect. In this context, the biological approaches have recently gained more and more attention. Growth factors, blood derivatives, such as platelet concentrates, and mesenchymal adult stem cells, either expanded or freshly isolated, are advocated amongst the most promising tool for the treatment of OA, especially in the early phases. Primarily targeted towards focal cartilage defects, these biological agents have indeed recently showed promising results to relieve pain and reduce inflammation in patients with more advanced OA as well, with the final aim to halt the progression of the disease and the need for joint replacement. However, despite of a number of satisfactory in vitro and pre-clinical studies, the evidences are still limited to support their clinical efficacy in OA setting.

Indexed as

Cartilage, ArticularPlatelet-Rich PlasmaRegenerationAdipose TissueDisease ProgressionEarly Medical InterventionHumansInflammationIntercellular Signaling Peptides and ProteinsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationOsteoarthritisOsteoarthritis, KneePainIntercellular Signaling Peptides and ProteinsCartilageGrowth factorsMesenchymal stem cellsMolecular therapyOsteoarthritis

Identifiers

PMID27120191
OpenAlexW2345293713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.